A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
Latest Information Update: 08 May 2025
At a glance
- Drugs NV01 A02 (Primary)
- Indications Autism spectrum disorder
- Focus Therapeutic Use
- Sponsors Neuroventi
Most Recent Events
- 08 May 2025 New trial record